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Dosage of Single Low-Dose 
Primaquine to Stop Malaria 
Transmission 
To The Editor—The World Health 
Organization (WHO) recommends 
the use of single low-dose primaquine 
(SLD-PQ) to reduce Plasmodium fal-
ciparum malaria transmission [1]. 
Chen et  al assessed the safety of 0.40 
and 0.50  mg/kg SLD-PQ usage in 
glucose-6-phosphate dehydrogen-
ase (G6PD)-deficient adult males in 
Mali, providing evidence that extend-
ing the upper bound of the therapeutic 
dose range of SLD-PQ is possible [2]. 
The Dominican Republic (DR) is now 
(2016–2020) under a strategic plan 
towards malaria elimination (a joint 
effort between Pan American Health 
Organization and the United Nations 
Millennium Development Goals); it is 
still considered a malaria endemic coun-
try with the highest risk in its far western 
region. DR is one of the few countries 
in the world where chloroquine is the 
recommended first-line treatment for 
uncomplicated P.  falciparum malaria, 
administered together with SLD-PQ in 
a 0.75-mg/kg regimen, with no alarming 
secondary effects reported or known to 
occur due to this regimen [3].
Because the DR population has a 
strong African ancestry influence [4], 
a high incidence of G6PD deficiency 
is expected to occur. We evaluated the 
G6PD A− allele (containing the path-
ogenic G202A substitution), classi-
fied as WHO class  III variant [5] and 
most prevalent in Africans [6], in 343 
febrile patients from DR. Samples were 
collected at the Jaime Mota Regional 
Hospital in Barahona (246), the Vinicio 
Calventi Hospital (6) and Robert Reid 
Cabral Hospital (2) in Santo Domingo, 
and the San José de Ocoa Hospital 
(1), as well as in primary health care 
centers in Barahona (73), Dajabón (6), 
Santo Domingo (5), La Altagracia (2), 
Bahoruco (1), and La Vega (1) prov-
inces. Samples were collected between 
2011 and 2016 with informed con-
sent and as approved by the DR insti-
tutions: Universidad Autónoma de 
Santo Domingo, Research Council of 
Faculty of Sciences, the National Health 
Research Department of the Ministry of 
Health and the Institute of Microbiology 
and Parasitology (IMPA) Bioethics 
Committee. All procedures contribut-
ing to this work comply with the eth-
ical standards of the relevant national 
and institutional committees on human 
experimentation and with the Helsinki 
Declaration of 1964, amended in 2008.
DNA was extracted from filter papers 
(104) and also from collected Rapid 
Diagnostic Test Cards (239) (First 
Response Malaria Ag. P.  falciparum 
(HRP2) Card Test, Premier Medical 
Corporation Ltd.) using NYZ Blood 
gDNA Isolation Kit (NZYTech). The 
reactions were run into a Biorad CFX96 
Touch Real-Time PCR Detection System 
using a commercial TaqMan single nucle-
otide polymorphism (SNP) genotyp-
ing assay (SNP ID: rs1050828; Applied 
Biosystems).
Results showed that the G6PD A− 
allele is present in 20.7% of the popu-
lation (71 samples) with 20 (5.8%) of 
Dominicans being male hemizygous or 
female homozygous and 51 (14.9%) of 
female Dominicans being heterozygous, 
correlating with frequencies observed in 
African populations [6].
Taken altogether, the experience in DR 
using SLD-PQ support the extension of the 
upper bound of the therapeutic dose range 
of SLD-PQ with successful clinical results.
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